Digital Therapeutic for Chronic Pain Feasibility Study

Sponsor
University of Washington (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06000007
Collaborator
National Center for Complementary and Integrative Health (NCCIH) (NIH)
100
2
9.5

Study Details

Study Description

Brief Summary

The investigators will conduct a 2-arm randomized control feasibility study to evaluate: 1) the feasibility of using the mobile app and an optional activity tracker, 2) the feasibility of conducting a 2-arm trial, and 3) estimate the effect size for planning for a larger efficacy trial based on our primary outcomes. The intervention arm will test a mobile app that aims to help people reduce pain interference who have chronic pain, as well as mental health issues with depression and anxiety. Participants in the intervention arm will also have the option to sense health data with a tracker that integrates with the app, which will inform the feasibility of this feature.

Condition or Disease Intervention/Treatment Phase
  • Device: 2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app
  • Other: Treatment as usual
Phase 3

Detailed Description

This study will evaluate the existing 2Morrow Chronic Pain Self-Management Program, in the form of a mobile app, as a digital therapeutic for improving patients' pain self management and function who suffer from chronic pain. Specifically, the investigators will conduct a 2-arm randomized control feasibility study to evaluate: 1) the feasibility of using the mobile app and an optional activity tracker, 2) the feasibility of conducting a 2-arm trial, and 3) estimate the effect size for planning for a larger efficacy trial based on our primary outcomes. The intervention arm will test a mobile app that aims to help people reduce pain interference who have chronic pain, as well as mental health issues with depression and anxiety. Participants in the intervention arm will also have the option to sense health data with a tracker that integrates with the app, which will inform the feasibility of this feature.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomized control feasibility study with two arms: intervention arm vs. control armRandomized control feasibility study with two arms: intervention arm vs. control arm
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Development and Implementation of a Behavioral Digital Therapeutic Designed to Support, Educate, Screen and Remotely Monitor Patients With Chronic Pain
Anticipated Study Start Date :
Aug 17, 2023
Anticipated Primary Completion Date :
May 31, 2024
Anticipated Study Completion Date :
May 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Treatment as usual

Treatment as usual arm entails the patients continuing to receive care from their primary care provider and any specialists they choose to get involved in their care.

Other: Treatment as usual
Treatment as usual entails continuing with treatment for chronic pain with the patient's primary care provider and any potential specialists they choose to engage with.

Active Comparator: Intervention arm

Intervention arm includes access to the digital therapeutic mobile app in addition to treatment as usual

Device: 2Morrow Chronic Pain Self-Management Program - digital therapeutic mobile app
2Morrow Chronic Pain Self-Management Program is delivered via a mobile app that engaged patients in evidenced based psychotherapy for chronic pain, including Acceptance and Commitment Therapy and Cognitive Behavioral Therapy based activities, to improve a patient's pain self management. The mobile app also offers the ability to track activities, screen for other problems, support for communicating with medical providers, and access a coach via texting.

Outcome Measures

Primary Outcome Measures

  1. PROMIS Pain Interference Scale - Short Form 6b [will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)]

    Brief survey of patient's perceived pain interference in their ability to function; scores are normed on a T-score with 50 as the mean, 10 as the standard deviation, and higher scores are worse

Secondary Outcome Measures

  1. Patient Health Questionnaire 9 (PHQ-9) [will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)]

    depression symptom measure; scores range from 0 to 27; higher scores are worse

  2. Generalized Anxiety Disorder 7 (GAD-7) [will be measured at baseline, 1 month, 3 months, and 6 months after enrollment (and start of intervention in the intervention arm)]

    anxiety symptom measure; scores range from 0-21; higher scores are worse

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • =18 years old

  • at least one ICD pain related diagnosis noted in the electronic health record (EHR)

  • at least 2 visits in a primary care clinic with at least one in the last 12 months

  • willing to use a mobile app in English

  • T-score for the PROMIS brief pain inventory of >= 55

  • access to a smartphone

  • willing to download and use a mobile app daily

Exclusion Criteria:
  • current cancer related diagnosis (to exclude cancer related chronic pain)

  • plans for surgery in next 3 months

  • pregnant

  • currently receiving hospice care

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Washington
  • National Center for Complementary and Integrative Health (NCCIH)

Investigators

  • Principal Investigator: Kari A Stephens, Ph.D., University of Washington

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Kari Stephens, Professor of Family Medicine, University of Washington
ClinicalTrials.gov Identifier:
NCT06000007
Other Study ID Numbers:
  • STUDY00016340
  • 1R44AT011593-01
First Posted:
Aug 21, 2023
Last Update Posted:
Aug 22, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Kari Stephens, Professor of Family Medicine, University of Washington
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 22, 2023